Loading…
Actuate Therapeutics, Inc. Common stock is projected to rise to $1.45 by 2027, a +30% move from its current price of $1.12. ACTU is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/5/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 6 | $1.06 | $1.12 | $1.18 | +0.13% |
| Aug 7 | $1.04 | $1.12 | $1.21 | +0.25% |
| Aug 8 | $1.02 | $1.12 | $1.24 | +0.38% |
| Aug 9 | $1.01 | $1.13 | $1.26 | +0.50% |
| Aug 10 | $0.9975 | $1.13 | $1.27 | +0.63% |
| Aug 11 | $0.9872 | $1.13 | $1.29 | +0.76% |
| Aug 12 | $0.9779 | $1.13 | $1.31 | +0.88% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.9779 | $1.13 | $1.31 | +0.88% |
| Week 2 | $0.9292 | $1.14 | $1.40 | +1.77% |
| Week 3 | $0.8954 | $1.15 | $1.48 | +2.67% |
| Week 4 | $0.869 | $1.16 | $1.55 | +3.58% |
| Week 5 | $0.8472 | $1.17 | $1.62 | +4.49% |
| Week 6 | $0.8288 | $1.18 | $1.68 | +5.41% |
| Week 7 | $0.8127 | $1.19 | $1.75 | +6.34% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma.
It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias.
The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.
ACTU is the common stock of Actuate Therapeutics, Inc., a healthcare company focused on cancer therapies. The stock trades with a current price of $1.17 and a market cap of $27.99M, and it is ranked 4496 by market capitalization.
The near-term price picture is bearish, with a 30-day range of $0.7943 to $1.72 and a current technical setup showing bearish sentiment. The longer-term forecast shows upside potential, with a sequence of yearly price projections. For example, 2027 shows an average price of $1.52 with a 29.7% ROI and a bullish sentiment, while 2040 projects an average of $2.35 with a 100.9% ROI and a bullish stance, and 2050 projects an average of $3.32 with a 184.1% ROI and a bullish stance.
A major floor 57.7% below — a decisive break under it would weaken the trend.
The nearest floor, 5.4% below — buyers have tended to step in here.
The nearest ceiling, 75.0% above — a clean break opens room to run.
A major ceiling 198.2% above — clearing it would confirm fresh momentum.
Key ACTU support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ACTU market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.11 | Buy | $1.11 | Buy |
| MA 10 | $1.13 | Sell | $1.16 | Sell |
| MA 20 | $1.29 | Sell | $1.28 | Sell |
| MA 50 | $1.63 | Sell | $1.64 | Sell |
| MA 100 | $2.08 | Sell | $2.30 | Sell |
| MA 200 | $3.90 | Sell | $3.54 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 36.28 | Neutral |
| Stoch RSI (14) | 56.82 | Neutral |
| CCI (20) | -71.40 | Neutral |
| Williams %R (14) | -89.47 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -21.43 | Sell |
| Bollinger %B (20,2) | 0.28 | Neutral |
| Stochastic %K (14) | 10.53 | Buy |
| TRIX (15) | -1.60 | Sell |
| Awesome (5,34) | -0.35 | Sell |
| Ultimate (7,14,28) | 35.12 | Neutral |
| Momentum (10) | -0.16 | Sell |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 1.09 | Buy |
| ADX (14) | 28.00 | Sell |
| ATR (14) | 0.07 | Info |
The 30-day technical picture is BEARISH, with RSI14 at 40. The SMA50 is $1.74 and the SMA200 is $4.04, indicating near-term resistance above the current price and notable downside risk before longer-term support is established.
Key near-term levels: support at $1.06 and resistance at $2.07. The 30-day price range runs from $0.7943 to $1.72, highlighting a tight trading window with limited upside momentum in the immediate term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.06 | $1.12 | $1.75 | 0% | Neutral | |
| $1.06 | $1.45 | $2.16 | +30% | Bullish | |
| $0.812 | $1.18 | $1.87 | +6% | Neutral | |
| $0.8345 | $1.28 | $2.13 | +15% | Neutral | |
| $0.7344 | $1.18 | $2.05 | +6% | Neutral | |
| $0.6088 | $1.03 | $1.84 | -8% | Neutral | |
| $0.75 | $1.32 | $2.44 | +18% | Neutral | |
| $0.8571 | $1.57 | $2.98 | +40% | Bullish | |
| $0.9076 | $1.73 | $3.37 | +54% | Bullish | |
| $0.8719 | $1.73 | $3.44 | +54% | Bullish | |
| $1.01 | $2.23 | $4.90 | +100% | Bullish | |
| $1.42 | $3.16 | $7.28 | +183% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.06 | $1.12 | $1.43 | +0.00% |
| September 2026 | $1.03 | $1.25 | $1.59 | +11.87% |
| October 2026 | $1.02 | $1.26 | $1.62 | +0.23% |
| November 2026 | $0.9953 | $1.24 | $1.63 | -1.24% |
| December 2026 | $1.05 | $1.32 | $1.75 | +6.11% |
Click any year to see its month-by-month ACTU forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Actuate Therapeutics, Inc. Common stock's 2026 outlook centres on $1.12, within a $1.06 to $1.75 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, ACTU could reach as high as $2.16, with a base case around $1.45 and support toward $1.06 — roughly +30% from $1.12. Buyers look set to stay in control over this stretch.
Expect ACTU to range from $0.812 to $1.87 through 2028. The $1.18 average target implies a +6% move from current prices. That is -18% versus the projected 2027 average. Price action looks broadly range-bound.
The ACTU price prediction for 2029 points to an average of $1.28 (low $0.8345, high $2.13) — a potential gain of +15% on today's $1.12. A consolidation phase looks the most probable path here.
In 2030, ACTU is projected to trade between $0.7344 and $2.05, averaging $1.18 — a potential gain of +6% from today's $1.12. That is -8% versus the projected 2029 average. Price action looks broadly range-bound.
Actuate Therapeutics, Inc. Common stock's 2031 outlook centres on $1.03, within a $0.6088 to $1.84 range. That is -13% versus the projected 2030 average. That marks a -8% change versus current levels. A consolidation phase looks the most probable path here.
By 2032, ACTU could reach as high as $2.44, with a base case around $1.32 and support toward $0.75 — roughly +18% from $1.12. Price action looks broadly range-bound.
Expect ACTU to range from $0.8571 to $2.98 through 2033. The $1.57 average target implies a +40% move from current prices. That is up +19% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The ACTU price prediction for 2034 points to an average of $1.73 (low $0.9076, high $3.37) — a potential gain of +54% on today's $1.12. Momentum favours further upside here.
In 2035, ACTU is projected to trade between $0.8719 and $3.44, averaging $1.73 — a potential gain of +54% from today's $1.12. That is 0% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
Actuate Therapeutics, Inc. Common stock's 2040 outlook centres on $2.23, within a $1.01 to $4.90 range. That is up +29% on the projected 2035 average. That marks a +100% change versus current levels. Momentum favours further upside here.
By 2050, ACTU could reach as high as $7.28, with a base case around $3.16 and support toward $1.42 — roughly +183% from $1.12. Buyers look set to stay in control over this stretch.
Investing $1,000 in ACTU today (≈ 892.857143 ACTU) could be worth
$2,825.31
+$1,825.31 (+183%) by 2050 · US Dollar
Based on the average projected ACTU price of $3.16 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ACTUwould be worth at today's price.
$1,000 invested in ACTU on Aug 5, 2025 (≈ 136.798907 ACTU) would be worth
$153.21
-$846.79 (-84.7%) today · 0.15× · US Dollar
Based on a ACTU entry price of $7.31 vs. today's $1.12.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.08 | $1,037.04 | +3.7% |
| 1 month ago | $1.4 | $800 | -20.0% |
| 3 months ago | $3.34 | $335.33 | -66.5% |
| 6 months ago | $4.41 | $253.97 | -74.6% |
| 1 year ago | $7.31 | $153.21 | -84.7% |
| All time (2.0y) ago | $8.61 | $130.08 | -87.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ACTU forecast.
Our base-case forecast reaches $2.20 around 2040.
Implied market cap at $2.20: $52.64M
The multi-year forecast shows mixed intermediate to long-run potential. By 2030, the average price is forecast at $1.23 with a ROI of 4.8% and sentiment NEUTRAL. In the longer horizon, 2040 is forecast to deliver an average of $2.35 with a ROI of 100.9% and sentiment BULLISH, while 2050 is forecast to deliver an average of $3.32 with a ROI of 184.1% and sentiment BULLISH.
The trajectory implies meaningful upside emerges in the 2040–2050 window, but there is variability across years (e.g., 2031 shows ROI -10). These figures are estimates and carry uncertainty, with outcomes dependent on factors beyond the numbers themselves.
Tap a question to reveal the answer.
The forecast for 2030 shows min $0.7598, avg $1.23, max $2.12, ROI 4.8%, sentiment NEUTRAL.
Yes. The near-term forecasts begin neutral in 2026 (min $1.06, avg $1.17, max $1.87, ROI 0%), followed by a bullish 2027 with avg $1.52 and ROI 29.7%.
The 2050 forecast max is $7.64; the 2050 average is $3.32 with ROI 184.1% and sentiment BULLISH.
Current price $1.17; market cap $27.99M; rank 4496.
30-day range is $0.7943 to $1.72; support is $1.06 and resistance is $2.07.
Actuate Therapeutics, Inc. Common stock Community Discussion
0Share your Actuate Therapeutics, Inc. Common stock price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.